Research programme: anticancer immunotherapeutics - BrightPath Biotherapeutics

Drug Profile

Research programme: anticancer immunotherapeutics - BrightPath Biotherapeutics

Alternative Names: GRN-1301; Neoantigen therapeutics - BrightPath Biotherapeutics; Neoantigen-based cancer vaccine-BrightPath Biotherapeutics

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BrightPath Biotherapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Non-small cell lung cancer

Most Recent Events

  • 27 Oct 2017 National Cancer Center Tokyo and BrightPath Biotherapeutics agree to co-develop neoantigen vaccine for Cancer
  • 11 Jul 2017 BrightPath Biotherapeutics plans a phase I trial for Non-small cell lung cancer in Japan in 2018 (BrightPath Biotherapeutics website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top